ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that there will be several clinical data presentations for compounds utilizing the Company's Targeted Antibody Payload (TAP) technology at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on June 4-8, 2010.
"These presentations at ASCO will include the first clinical data for our IMGN388 compound for solid tumors, and also the first data for a TAP compound used in a combination regimen," commented Daniel Junius, President and CEO. "Our clinical pipeline not only continues to grow through progress with additional TAP compounds, but also to mature through an increase in planned and ongoing advanced clinical trials."
TAP-Related Presentations and Discussions at ASCO
Abstract #1012: A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for women with HER2-positive, locally advanced or metastatic breast cancer who were previously treated with trastuzumab
- Poster presentation: Saturday, June 5, 8:00 am - 12:00 noon in E450b
- Poster discussion session: Saturday, June 5, 12:00 noon - 1:00 pm in E Hall D1
Abstract #1016: Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients with metastatic breast cancer who had progressed on prior HER2-directed therapy
- Poster presentation: Saturday, June 5, 8:00 am - 12:00 noon in E450b
- Poster discussion session: Saturday, June 5, 12:00 noon - 1:00 pm in E Hall D1
Abstract #3058: A phase I dose-escalation study of IMGN388 in patients with solid tumors
- Poster presentation: Monday, June 7, 8:00 am - 12:00 noon in S Hall A2
Additionally, John Lambert, Ph.D., Executive Vice President and Chief Scientific Officer of ImmunoGen, will be participating on the panel, "New Targeted Therapies for Resistant Cancers" being held on Monday, June 7, in conjunction with ASCO.
Revolutionizing brain tumor treatment: the rise of AI in neuro-oncology